Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Under Waxman’s microscope

Executive Summary

Public health consequences of drug-resistant microbes will be examined Nov. 7 by the House Oversight and Government Reform Committee. Reports about methicillin-resistant Staphylococcus aureus have focused public attention on the issue and may provide impetus for federal legislation. Sens. Sherrod Brown, D-Ohio, and Orrin Hatch, R-Utah, introduced Oct. 31 an antimicrobial resistance bill that already is pending in the House (1"The Pink Sheet" Oct. 15, 2007, p. 9). The proposed law would improve "our grasp on resistance and ways to control it," notes Donald Peretz, president of the Infectious Diseases Society of America. IDSA has been urging Congress for several years to create incentives for the development of new drugs to fight microorganisms resistant to existing therapies...

You may also be interested in...

Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill

Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J

Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials?

The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.

Nichi-Iko Aims To Regroup As It Enters Turnaround Process

Japan’s Nichi-Iko has formally entered a business turnaround alternative dispute resolution process that will see the company outline a business rehabilitation plan involving management restructuring and a fresh profit structure, following financial underperformance in the wake of recent quality issues.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts